Greg Jester Email & Phone Number

Humanigen is re-positioning and developing its proprietary monoclonal antibodies to meet some critical unmet needs in today's most advanced cancer science. Humanigen’s focus is on making chimeric antigen receptor T-cell (CAR-T) therapy safer, better and more routine. Our lead asset lenzilumab is poised to begin testing for possible prophylaxis of neurotoxicity and cytokine release syndrome related to CAR-T treatment. We are dedicated to cutting-edge science and generating new, transformational ideas in our industry. We will lead by example with integrity and creative and concrete operational change. We are completely transforming the company to bring innovative value to patients, partners and all our stakeholders through the pursuit of leading immunotherapy science.

Monmouth Junction, New Jersey, Us

Aug. 2014 to present: Interim Controller, $40 million PE owned generic pharmaceutical company. Provide financial and accounting leadership for recently acquired generic pharmaceutical companyMar. 2014 to Aug. 2014: Financial Consultant, Drug Device company. Projects included assistance in developing European commercial operations for recently approved product, extensive financial modeling, assistance with 10K/Q and leading search for new audit and tax services.

CFO for $5 million food brokerage serving warehouse club store segment.

Irvington , Ny, Us

House Party is the leading social media company that combines digital, word-of-mouth and experiential marketing to build brands and drive sales. We generate millions of consumer conversations and recommendations, online and off, through our passionate community of social influencers, proprietary digital platform and memorable in-home events for the world's best-loved brands.

Directed all financial activities for two operating companies in the life sciences sector: Alvogen, Inc. a start-up development stage specialty pharmaceutical company with global development activities funded through private equity investors with a cash commitment in excess of $30 million and Norwich Pharmaceuticals, Inc. a $40 million turn-around commercial and pilot scale pharmaceutical contract manufacturer/developer.

Directed all financial, investor relations and administrative activities for a publicly held clinical stage oncology company with four simultaneous development-stage projects.

Managed 40-person team responsible for corporate and operational accounting, financial reporting and analysis, budgeting and forecasting, public filings, execution of mergers and acquisitions, and execution of product development contracts. Provided financial management, strategic development and functional oversight to support corporate growth from $300 million to $1.3 billion in revenues.

New York, Ny, Us

Bsba, Accounting And Marketing

Bsba, Accounting And Marketing